Withdrawing Payment for Nonscientific Drug Therapy: Intended and Unexpected Effects of a Large-Scale Natural Experiment

JAMA: The Journal of the American Medical Association

Volumn 263, Issue 6, 1990, Pages 831-839

  Soumerai, Stephen B ^a   Ross Degnan, Dennis ^a   Gortmaker, Steven ^b   Avorn, Jerry ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG SCREENING; ECONOMIC ASPECT; FINANCE; HEALTH CARE MANAGEMENT; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL;

ADULT; CHILD; COHORT STUDIES; DRUG THERAPY; DRUG UTILIZATION; HUMAN; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; MIDDLE AGE; NEW JERSEY; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES;

EID: 0025056932     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1990.03440060077036     Document Type: Article

References (43)

1. Lurie N, Ward NB, Shapiro MF, Brook RH. Termination from Medi-Cal: does it affect health? N Engl J Med. 1984;311:480-484.
2. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
3. Holahan JF, Cohen JW. Medicaid: The Tradeoff Between Cost-Containment and Access to Care. Washington, DC: The Urban Institute Press; 1986.
4. Smith T. Limited lists of drugs: lessons from abroad. Br Med J. 1985;290:532-534.
5. WHO Expert Committee. The Use of Essential Drugs. Geneva, Switzerland: World Health Organization; 1985.
6. Eisenberg JM. Doctors’ Decisions and the Cost of Medical Care. Ann Arbor, Mich: Health Administration Press; 1986:129-131.
7. Cypress BK. Drug Utilization in General and Family Practice by Characteristics of Physicians and Office Visits: National Ambulatory Medical Care Survey, 1980. Hyattsville, Md: National Center for Health Statistics; 1983;87.
8. US Pharmaceutical Industry, 1986-1987: Annual Survey Report. Washington, DC: Pharmaceutical Manufacturers Association; 1988.
9. Soumerai SB, Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q. 1984;62:447-474.
10. Steel K, Gertman PM, Crescenzi C, Anderson J. Iatrogenic illness on a general medical service at a university hospital. N Engl J Med. 1981;304:638-42.
11. Silverman M, Lee PR. Pills, Profits, and Politics. Berkeley: University of California Press; 1974:107-137.
12. National Research Council. Drug Efficacy Study: A Report to the Commissioner of Food and Drugs. Washington, DC: National Technical Information Service; 1969.
13. Hecht A. A long reach back to assure drug quality. FDA Consumer. 1984;18:15.
14. Smith DM, McKercher PL. The elimination of selected drug products from the Michigan Medicaid formulary: a case study. Hosp Formulary. 1984;19: 366-372.
15. Smith MC, Maclayton DW. The effect of closing a Medicaid formulary on the prescription of analgesic drugs. Hosp Formulary. 1977;12:36-41.
16. Ferrando C, Henman MC, Corrigan OL. Impact of a nationwide limited prescribing list: preliminary findings. Drug Intell Clin Pharm. 1987;21: 653-658.
17. Cook TD, Campbell DT. Quasi-Experimentation: Design and Analysis Issues for Field Settings. Boston, Mass: Houghton Mifflin Co; 1979.
18. Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care. 1976;14:166-172.
19. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically-based ‘detailing.’ N Engl J Med. 1983;308:1457-1463.
20. Schaffner W, Ray WA, Federspiel CF, Miller WO. Improving antibiotic prescribing in office practice: a controlled trial of three educational methods. JAMA. 1983;250:1728-1732.
21. Soumerai SB, Avorn J. Economic and policy analysis of university-based drug ‘detailing.’ Med Care. 1986;24:313-331.
22. National Technical Information Service. Medicaid Data as a Source for Postmarketing Surveillance Information, Vol. I: Technical Report. Research Triangle Park, NC: Research Triangle Institute; 1984.
23. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369.
24. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association; 1986.
25. American Hospital Formulary Service. Drug Information 86. Bethesda, Md: American Society of Hospital Pharmacists; 1986.
26. Drug Facts & Comparisons. St Louis, Mo: JB Lippincott; 1983.
27. Ainley W, ed. Martindale, William The Extrapharmacopeia: Incorporating Squires Companion. 27th ed. London, England: Pharmaceutical Press; 1977.
28. SAS User’s Guide: Statistics. 1982 ed. Cary, NC: SAS Institute; 1982.
29. Rao P, Miller RL, eds. Applied Econometrics. Belmont, Calif: Wadsworth Publishing Co; 1971.
30. Gortmaker SL, Clark CJG, Graven SN, Sobol AM, Geronimus A. Reducing infant mortality in rural America: evaluation of the Rural Infant Care Program. Health Serv Res. 1987;22:91-115.
31. Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am J Public Health. 1981;71:38-48.
32. Jang R. Medicaid formularies: a critical review of the literature. J Pharmaceutical Marketing & Management. 1988;2:39-61.
33. Lohr KN, Brook RH, Kamberg CJ, et al. Use of medical care in the RAND Health Insurance Experiment: Diagnosis- and service-specific analyses in a randomized controlled trial. Med Care. 1986;24(suppl):S1-S87.
34. Hefner DL. Cost-effectiveness of a Restrictive Drug Formulary: Louisiana vs Texas. Washington, DC: National Pharmaceutical Council; 1980.
35. Hammel RW. Insights into public assistance medical care expenditures. JAMA. 1972;219:1740-1744.
36. Melmon KL. Preventable drug reactions: causes and cures. N Engl J Med. 1971;284:1361-1368.
37. Spiro HM. Doctors, Patients and Placebos. New Haven, Conn: Yale University Press; 1986.
38. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med. 1989;28:577-582.
39. Marsh GN. ‘Curing’ minor illness in general practice. Br Med J. 1977;2:1267-1269.
40. Woodward RS, Medoff G, Smith MD, Gray JL III. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school—affiliated hospital. Am J Med. 1987;83:817-823.
41. Avorn J, Soumerai SB, Taylor W, Wessels MR, Janousek J, Weiner M. Reduction of incorrect antibiotic dosing through a structured educational order form. Arch Intern Med. 1988;148:1720-1724.
42. Buchwald D, Soumerai SB, Vandevanter N, Wessels MR, Avorn J. Implementation of a hospital-wide reduction in clindamycin dosage scheduled: effects on clinical outcomes. Rev Infect Dis. 1989;11:619-624.
43. Tartter PI, Barron DM. Unnecessary blood transfusion in elective colorectal cancer surgery. Transfusion. 1985;25:113-115.